Anti-D Rho immunoglobulin - Mitsubishi Tanabe

Drug Profile

Anti-D Rho immunoglobulin - Mitsubishi Tanabe

Alternative Names: Anti-D Human Immunoglobulin; Dry anti-Rho(D) immune human globulin

Latest Information Update: 25 May 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class Immunoglobulins
  • Mechanism of Action Immunoglobulin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemolytic disease of newborn

Most Recent Events

  • 20 May 2011 Label extension approved for Haemolytic disease of newborn (Prevention, Administration at around 28 weeks gestation, and after miscarriage or induced abortion) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top